NVAX

Novavax, Inc.

5.30 USD
+0.00 (+0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Novavax, Inc. stock is up 29.15% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.62% of the previous 28 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 19:43 17 Jan, 2025 2.50 CALL 350 1284
22 Feb 19:43 17 Jan, 2025 2.50 CALL 122 1284
22 Feb 20:28 17 Jan, 2025 5.00 CALL 169 14405
22 Feb 20:35 17 Jan, 2025 1.50 CALL 95 95
23 Feb 14:55 15 Mar, 2024 5.00 PUT 982 4082
23 Feb 15:10 15 Mar, 2024 6.00 CALL 1113 94
23 Feb 15:10 15 Mar, 2024 6.00 CALL 1352 94
23 Feb 15:22 19 Apr, 2024 7.50 CALL 744 20768
23 Feb 16:16 17 Jan, 2025 7.50 PUT 450 1795
23 Feb 17:03 19 Apr, 2024 7.50 CALL 1500 20768

About Novavax, Inc.

Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.